ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus

IMPT-514 is the first-and-only CD19/CD20 CAR T-cell therapy in development for lupus Designed to reset the immune system, IMPT-514 is a one-time treatment option with potential to replace the need for chronic immune suppression Initial efficacy and safety data from Phase 1b/2 dose…